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West Nile Virus (WNV) is a mosquito-borne flavivirus
with a rapidly expanding global distribution. Infection
causes severe neurological disease and fatalities in both
human and animal hosts. The West Nile viral protease
(NS2B-NS3) is essential for post-translational process-
ing in host-infected cells of a viral polypeptide precur-
sor into structural and functional viral proteins, and its
inhibition could represent a potential treatment for vi-
ral infections. This article describes the design, expres-
sion, and enzymatic characterization of a catalytically
active recombinant WNV protease, consisting of a 40-
residue component of cofactor NS2B tethered via a non-
cleavable nonapeptide (G4SG4) to the N-terminal 184
residues of NS3. A chromogenic assay using synthetic
para-nitroanilide (pNA) hexapeptide substrates was
used to identify optimal enzyme-processing conditions
(pH 9.5, I < 0.1 M, 30% glycerol, 1 mM CHAPS), preferred
substrate cleavage sites, and the first competitive inhib-
itor (Ac-FASGKR-H, IC50 1 M). A putative three-di-
mensional structure of WNV protease, created through
homology modeling based on the crystal structures of
Dengue-2 and Hepatitis C NS3 viral proteases, provides
some valuable insights for structure-based design of po-
tent and selective inhibitors of WNV protease.
The West Nile Virus (WNV)1 was first detected in a woman
living in the West Nile region of Uganda almost 70 years ago
(1). WNV is a member of the Flaviviridae family that also
includes hepatitis C, Kunjin, yellow fever, Dengue, St. Louis,
and Japanese encephalitis viruses (1). WNV is transmitted via
mosquitoes from avian reservoir hosts to vertebrate dead-end
hosts that include humans and horses. Endemic in humans in
parts of Africa, Europe, and the Middle East, previous viral
outbreaks were mostly detected as asymptomatic infections or
mild febrile disease states (2). However, recent outbreaks in
Israel (1998), Romania (1996), and the United States (1999) (3)
have been associated with more serious neurological pathology
and fatal infections. During the last 5 years, WNV has spread
rapidly throughout the United States (4,156 infections and 284
deaths in 44 states in 2002, 9862 infections and 264 deaths in
2003),2 Canada, and Mexico, as well as appearing recently in
the United Kingdom (5). This rapid global spread, even through
developed countries, has prompted widespread implementation
of prevention strategies. No vaccines or therapeutic treatments
for WNV infections are yet available.
Like other members of the Flaviviridae family, WNV con-
tains a single-stranded, positive-sense RNA genome, which
encodes three structural proteins (capsid (C), membrane (M),
envelope (E)), and seven non-structural proteins (NS1, NS2A,
NS2B, NS3, NS4A, NS4B, NS5) (1, 3). The genome is initially
translated as a single, large polyprotein precursor. Post-trans-
lational cleavages of the viral polyprotein precursor in the
cytoplasm of host-infected cells are necessary to produce the
separate structural and functional viral proteins that are es-
sential for assembly of new viral progeny. These cleavages are
performed by both host enzymes (including signalases and
furin) and by a viral protease encoded by the N-terminal-third
of NS3 (Fig. 1). This NS3 viral protease, which is a trypsin-like
serine protease with a functional catalytic triad (His51, Asp75,
Ser135), is absolutely essential (along with viral-encoded cofac-
tor NS2B) for viral replication and is itself autocatalytically
cleaved from the polypeptide precursor. By analogy with the
homologous Dengue virus NS3 protease, for which our trunca-
tion studies had previously shown that a 40-residue hydro-
philic domain of NS2B is necessary for catalytic activity of the
NS3 protease, (6) we infer below that a similar sequence within
the WNV NS2B is likely necessary for catalytic activity of the
WNV NS3 protease. The remainder of NS2B encodes 3 hydro-
phobic domains, believed to be involved in membrane associa-
tion and localization of the enzyme to convoluted membrane
regions on the endoplasmic reticulum (7). The structure of
WNV NS3 protease is unknown, but there are reported crystal
structures for related NS3 proteases of hepatitis C virus (HCV)
(8) and Dengue virus (DEN2) (9). The structure of the latter
protease was however determined in the absence of the NS2B
cofactor and was thus an inactive enzyme.
By virtue of its essential function in post-translational proc-
essing of the viral polypeptide, WNV NS3 protease is impli-
cated as a potential target for development of therapeutics that
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prevent viral replication. Precedents for inhibitors of viral pro-
teases being potential antiviral drugs lie in the success of
inhibitors of proteases of the human immunodeficiency viruses
(HIV), currently the most effective treatments for humans with
HIV/AIDS (10, 11), and in the early promise being shown by
inhibitors of the NS3 protease of hepatitis C virus (12). This
article describes the design and construction of a catalytically
active recombinant WNV NS2B-NS3 protease enzyme con-
struct, the characterization of factors that influence enzymatic
processing of short synthetic chromogenic substrates contain-
ing para-nitroanilide (pNA), the first reported inhibitor of
WNV protease, and the development of a three-dimensional
homology-modeled structure of the WNV NS3 protease based
on the known crystal structures of Dengue NS3 protease and
HCV NS3 protease complexed with cofactor NS4A. It is ex-
pected that the recombinant protease cofactor construct, chro-
mogenic assay, and homology structure might be useful for
future structure-based design of even more potent and selective
inhibitors of the WNV NS3 protease. Such inhibitors might
form the basis for developing an antiviral therapy for the treat-
ment of WNV infections.
EXPERIMENTAL PROCEDURES
General Methods—Protected amino acids and resins were obtained
from Auspep, Novabiochem and PepChem. Trifluoroacetic acid, piperi-
dine, DIPEA, DCM, and DMF (peptide synthesis grade) were purchased
from Auspep. All other materials were reagent grade unless otherwise
stated. Crude peptides were purified by reverse-phase HPLC on a
Vydac C18, 10–15 m, 300 Å, 50  250 mm) column, using a gradient
mixture of solvent (A) 0.1% trifluoroacetic acid/water and (B) 0.1%
trifluoroacetic acid/10% water/90% acetonitrile. Analytical HPLC was
performed on a Waters system equipped with a 717 plus autosampler,
660 controller and a 996 photodiode array detector, using a reverse-
phase Phenomenex Luna C18, 5 m, 100 Å, 250  4.6-mm column.
Purified peptides were characterized by analytical HPLC (linear gradi-
ent 0–100% B over 30 min), mass spectrometry, and NMR. The molec-
ular weight of the peptides (1 mg/ml) was determined by electrospray
mass spectrometry on a Micromass LCT mass spectrometer. 1H NMR
spectra were recorded on samples containing 4 mM peptide in Me2SO-d6
(550 l) on a Bruker Avance 600 spectrometer at 298 K. Proton assign-
ments were determined by TOCSY (80 ms mixing time), DQF-COSY,
ECOSY, and NOESY (350 ms mixing time) spectra using the sequential
assignment method (13). All spectra were processed on Silicon Graphics
R10000 or R12000 workstations using XWINNMR 2.6 (Bruker BioSpin
GmbH, Rheinstetten, Federal Republic of Germany).
Plasmid Construction—WNV (strain NY99–4132)-infected Vero cell
RNA was generously provided by R. A. Hall and D. J. Nisbet (Univer-
sity of Queensland, Australia). cDNA was generated using the WNV
NS3pro.RHindIII reverse primer (5-GCCCCCAAGCTTACAGCATCT-
CAGGTTCGAAT-3; restriction sites are underlined), which was then
used as template in the generation of the WNV NS3pro and the WNV
CF40.Gly.NS3pro constructs. WNV NS3pro was generated by a PCR
reaction using the primers WNV NS3pro.FBamH1 5-GCCCCTGGAT-
CCGGTGGCGTATTGTGGGATACT-3 and WNV NS3pro.RHindIII 5-
GCCCCCAAGCTTACAGCATCTCAGGTTCGAAT-3. WNV CF40.GLY.
NS3PRO was generated in two separate PCR reactions employing the
primer pairs WNV CF40.FBamH1 5-CGATGAC GGCGGATCCACAG-
ATATGTGGATTGAGAGAACG-3/WNV CF40.Gly.R 5-CCCGCCTCC-
ACCACTACCTCCCCCGCCCTTCCAAGGAGCACCTGGATC-3 and
WNV NS3proGly.F 5-GGCGGGGGAGGTAGTGGTGGAGGCGGGGG-
AGGCGTATTGTGGGA TACT-3/WNV NS3pro.RHindIII 5-GCCCCC-
AAGCTTACAGCATCTCAGGTTCGAAT-3 to generate PCR products
encoding the essential 40 residue cofactor domain of NS2B and the 184
residue NS3pro genes, flanked with partial glycine linker sequences.
These PCR products were then joined by overlapping PCR using the outer
primers WNV CF40.FBamHI and WNV NS3pro.RHindIII. The resulting
PCR products, designated WNV NS3pro and CF40.Gly.NS3pro, com-
prised the 184 residue NS3 protease domain alone and the 40 residue
essential cofactor domain of NS2B linked to the 184 residue NS3 protease
via a flexible nonapeptide glycine linker (Gly4SerGly4), respectively.
These were then digested with BamHI and HindIII and cloned into pQE9.
The identity of these constructs, designated pQE9 WNV NS3pro and
pQE9 WNV CF40.Gly.NS3pro was confirmed by automated sequence
analysis.
Enzyme Expression and Purification—The pQE9 WNV CF40.-
Gly.NS3pro vector was used to allow high level, inducible expression of
N-terminal hexahistidine-tagged recombinant proteins. Cultures of
Escherichia coli strain SG13009 transformed with the expression plas-
mids were grown in 500 ml of LB medium containing 100 g/ml ampi-
cillin and 25 g/ml kanamycin at 37 °C until OD600 reached 0.5. Ex-
pression of the recombinant protein was induced by the addition of
isopropyl--D-thiogalactopyranose (IPTG) to a final concentration of 0.3
mM and incubated for an additional 3 h at 22 °C. The cells were then
harvested by centrifugation and stored at 20 °C.
For protein purification, the cell pellets were thawed and resus-
pended in 5 ml of lysis buffer (50 mM HEPES, pH 7.5, 300 mM NaCl,10
mM imidazole, 5% glycerol) per 1 g of wet pellet. To prevent proteolytic
cleavage of protein during cell lysis and purification the following
protease inhibitors were added to give the final concentration of 1 g/ml
aprotinin, 1 g/ml leupeptin, 1 g/ml benzamide, 1 mM PMSF, and 10
g/ml TLCK. The resuspended cells were lysed by three passes through
a French Press at a pressure of 1000 Pascals and then centrifuged at
27,000 g for 20 min at 4 °C. The recombinant proteases, tagged at the
N terminus by a hexahistidine sequence, were purified by affinity
chromatography on a Ni2-nitrilotriacetic acid-agarose column (Qia-
gen). A 1-cm column was pre-equilibrated with 30 ml of column buffer
(50 mM HEPES, pH 7.5, 300 mM NaCl, 10 mM imidazole, 5% glycerol),
and then the resin was removed and mixed with the supernatant of the
cell lysates. These mixtures were then incubated at 4 °C on a shaker for
30 min to allow the His-tagged protein to bind to the Ni2 resin. The
columns were re-packed and washed with 30 ml of column buffer
containing 20 mM imidazole before eluting the protein into 6  1 ml
fractions with column buffer containing 100 mM imidazole. The pre- and
post-IPTG induction samples, soluble and insoluble fractions, and the
elution fractions were analyzed by 12% SDS-PAGE.
Substrate Synthesis—The pNA substrates corresponding to the na-
tive WNV NS3 protease cleavage sites Ac-DPNRKR-pNA (NS2A-
NS2B), Ac-LQYTKR-pNA (NS2B-NS3), Ac-FASGKR-pNA (NS3-NS4A),
and Ac-KPGLKR-pNA (NS4A-NS5) were synthesized by a reported
method (15).
Ac-DPNRKR-pNA—Rt  16.4 min. ESMS [MH]  947.8, [M2H]/
2 474.4. 1H NMR (Me2SO-d6)  12.37 (br s, 1H, AspOH), 10.58 (s, 1H,
pNA-NH), 8.27 (d, 1H, AspNH), 8.22 (d, 2H, pNAArH), 8.15 (d, 1H,
Arg6NH), 8.00 (d, 1H, AsnNH), 7.86 (d, 1H, LysNH),7.84 (d, 2H,
pNA-ArH), 7.73 (d, 1H, Arg4NH), 7.67 (m, 3H, LyszNH3), 7.60 (t, 1H,
Arg6NH),7.50 (t, 1H, Arg4NH), 7.5–6.6 (8H, m, 4xArgNH2), 7.42 (s,
1H, AsnNH), 6.97 (s, 1H, AsnNH), 4.81 (m, 1H, AspCH), 4.45 (m,
1H, AsnCH), 4.34 (m, 1H, Arg6CH), 4.25 (dd, 1H, ProCH), 4.22 (m,
1H, LysCH), 4.21 (m, 1H, Arg4CH), 3.68 (m, 1H, ProCH),3.61 (m,
1H, ProCH), 3.12 (m, 2H, Arg6CH2), 3.07 (m, 2H, Arg4CH2), 2.73 (m,
2H, LysCH2), 2.68 (dd, 1H, AspCH), 2.58 (dd, 1H, AsnCH), 2.44 (m,
1H, AspCH), 2.43 (m, 2H, AsnCH), 2.03 (m, 1H, ProCH), 1.87 (m,
2H, ProCH2), 1.83 (m, 1H, ProCH), 1.80 (s, 3H, Ac-CH3), 1.77 (m, 1H,
Arg4CH), 1.77 (m, 1H, Arg6CH), 1.67 (m, 1H, LysCH), 1.65 (m, 1H,
Arg6CH), 1.57 (m, 1H, LysCH), 1.55 (m, 1H, Arg6CH), 1.50 (m, 1H,
Arg4CH), 1.50 (m, 1H, Arg4CH), 1.50 (m, 1H, LysCH), 1.50 (m, 2H,
FIG. 1. Native processing of West Nile Virus polyprotein by
proteases. Polyprotein processing by host cell proteases (upper scheme,
black arrows) and by virus-encoded NS2B/NS3 protease (open arrows).
The proteolytic domain of NS3 (NS3pro) and NS2B cofactor (shaded) is
expanded (lower scheme) to show cleavage site (open arrow), catalytic
triad (asterisks), hydrophobic domains of NS2B (solid boxes), and min-
imum 40-residue domain of cofactor NS2B required for catalytic activ-
ity. The recombinant constructs used herein: NS3pro consists of the
NS3pro domain in the absence of cofactor and CF40.Gly.NS3pro com-
prises this 40-residue cofactor domain (CF40) linked via a flexible
sequence (GGGGSGGGG) to NS3pro.
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LysCH2), 1.48 (m, 1H, Arg6CH), 1.33 (m, 1H, LysCH). HRMS cal-
culated for C39H62N16O12 [MH]
  947.4806, found 947.4782;
[M2H]/2  474.2439, found 474.2443.
Ac-LQYTKR-pNA—Rt  18.7 min. ESMS [MH]  970.6, [M2H]/
2  485.8. 1H NMR (Me2SO-d6)  10.60 (s, 1H, pNA-NH), 9.15 (s, 1H,
TyrzOH), 8.26 (d, 1H, ArgNH), 8.22 (d, 2H, pNA-ArH), 8.19 (d, 1H,
GlnNH), 8.07 (d, 1H, LeuNH), 7.90 (d, 1H, LysNH), 7.86 (d, 1H,
TyrNH), 7.84 (d, 2H, pNA-ArH), 7.80 (d, 1H, ThrNH), 7.64 (m, 3H,
LyszNH3), 7.51 (t, 1H, Arg6NH), 7.4–6.6 (4H, m, 2xArgNH2), 7.24 (s,
1H, GlnNH), 7.00 (d, 2H, 2xTyrCH), 6.79 (t, 1H, GlnNH), 6.79 (d, 2H,
2xTyrCH), 4.93 (s, 1H, ThrOH), 4.46 (m, 1H, TyrCH), 4.35 (m, 1H,
ArgCH), 4.30 (m, 1H, LysCH), 4.22 (m, 1H,ThrCH), 4.19 (m, 1H,
LeuCH), 4.12 (m, 1H, GlnCH), 3.98 (m, 1H, ThrCH), 3.11 (m, 2H,
ArgCH2), 2.94 (dd, 1H, TyrCH), 2.74 (m, 2H, LysCH2), 2.71 (m, 1H,
TyrCH), 2.06 (m, 1H, GlnCH), 2.00 (m, 1H, GlnCH), 1.86 (s, 3H,
Ac-CH3), 1.80 (m, 1H, GlnCH), 1.76 (m, 1H, ArgCH), 1.69 (m, 1H,
LysCH), 1.69 (m, 1H, GlnCH), 1.65 (m, 1H, ArgCH), 1.58 (m, 1H,
LeuCH), 1.56 (m, 1H, LysCH), 1.56 (m, 1H, ArgCH), 1.53 (m, 1H,
LysCH), 1.51 (m, 2H, LysCH2), 1.48 (m, 1H, ArgCH), 1.42 (m, 1H,
LeuCH), 1.39 (m, 1H, LeuCH), 1.33 (m, 1H, LysCH), 1.05 (d, 3H,
ThrCH3), 0.86 (d, 3H, LeuCH3), 0.81 (d, 3H, LeuCH3. HRMS calcu-
lated for C44H67N13O12 [MH]
  970.5105, found 970.5098; [M2H]/
2  485.7589, found 485.7601.
Ac-FASGKR-pNA—Rt  18.1 min. ESMS [MH]  827.6, [M2H]/
2  414.3. 1H NMR (Me2SO-d6)  10.61 (s, 1H, pNA-NH), 8.30 (d, 1H,
ArgNH), 8.22 (d, 2H, pNA-ArH), 8.21 (d, 1H, AlaNH), 8.12 (t, 1H,
GlyNH), 8.11 (d, 1H, PheNH), 7.94 (d, 1H, LysNH), 7.87 (d, 1H,
SerNH), 7.84 (d, 2H, pNA-ArH), 7.66 (m, 3H, LyszNH3), 7.58 (t, 1H,
ArgNH), 7.46–6.65 (4H, m, 2xArgNH2), 7.27–7.22 (m, 4H, PheArH),
7.20–7.14 (m, 1H, PheArH), 5.04 (s, 1H, SerOH), 4.48 (m, 1H, PheCH),
4.30 (m, 1H, ArgCH), 4.31 (m, 1H, AlaCH), 4.30 (m, 1H, LysCH),
4.23 (m, 1H, SerCH), 3.78 (dd, 1H, GlyCH), 3.71 (dd, 1H,
GlyCH),3.62 (m, 1H, SerCH), 3.55 (m, 1H, SerCH), 3.11 (m, 2H,
ArgCH2), 2.99 (dd, 1H, PheCH), 2.72 (m, 2H, LysCH2), 2.71 (m, 1H,
PheCH), 1.76 (m, 1H, ArgCH), 1.74 (s, 3H, Ac-CH3), 1.66 (m, 1H,
ArgCH), 1.64 (m, 1H, LysCH),1.56 (m, 1H, ArgCH),1.51 (m, 1H,
LysCH), 1.50 (m, 2H, LysCH2), 1.49 (m, 1H, LysCH),1.48 (m, 1H,
ArgCH), 1.30 (m, 1H, LysCH),1.22 (d, 3H, AlaCH3). HRMS calcu-
lated for C37H54N12O10 [MH]
  827.4159, found 827.4186; [M2H]/
2  414.2116, found 414.2130.
Ac-KPGLKR-pNA—Rt  16.9 min. ESMS [MH]  860.7, [M2H]/
2  430.8. 1H NMR (Me2SO-d6)  10.58 (s, 1H, pNA-NH), 8.23 (d, 2H,
pNA-ArH), 8.19 (t, 1H, GlyNH), 8.18 (d, 1H, ArgNH), 8.05 (d, 1H,
Lys1NH), 7.95 (d, 1H, Lys5NH), 7.84 (d, 2H, pNA-ArH), 7.76 (d, 1H,
LeuNH), 7.68 (m, 6H, 2xLyszNH3), 7.7–6.5 (4H, m, 2xArgNH2), 7.61
(t, 1H, Arg6NH), 4.47 (m, 1H, Lys1CH), 4.36 (m, 1H, ArgCH), 4.30
(m, 1H, LeuCH), 4.26 (m, 1H, ProCH), 4.24 (m, 1H, Lys5CH), 3.68
(m, 2H, GlyCH2), 3.67 (m, 1H, ProCH), 3.56 (m, 1H, ProCH), 3.11
(m, 2H, ArgCH2), 2.75 (m, 2H, Lys1CH2), 2.73 (m, 2H, Lys5CH2),
2.05 (m, 1H, ProCH), 1.93 (m, 1H, ProCH), 1.85 (m, 1H, ProCH),
1.82 (s, 3H, Ac-CH3), 1.80 (m, 1H, ProCH), 1.75 (m, 1H, ArgCH), 1.66
(m, 1H, Lys5CH), 1.65 (m, 1H, ArgCH), 1.63 (m, 1H, Lys1CH), 1.56
(m, 1H, Lys5CH), 1.56 (m, 1H, ArgCH), 1.56 (m, 1H, LeuCH), 1.53
(m, 1H, LysCH), 1.51 (m, 2H, Lys1CH2), 1.50 (m, 2H, Lys5CH2), 1.49
(m, 1H, Lys1CH), 1.49 (m, 1H, Lys1CH), 1.48 (m, 1H, LeuCH), 1.47
(m, 1H, ArgCH), 1.43 (m, 1H, LeuCH), 1.32 (m, 1H, Lys1CH), 1.32
(m, 1H, Lys5CH), 0.87 (d, 3H, LeuCH3), 0.83 (d, 3H, LeuCH3).
HRMS calculated for C39H65N13O9 [MH]
  860.5101, found
860.5061; [M2H]/2  430.7587, found 430.7617.
Inhibitor Synthesis—The peptide aldehyde Ac-FASGKR-H was syn-
thesized by the method of Siev and Semple (16). Ac-FASGKR-H (Rt 
15.5 min): ESMS [MH]  691.4. HRMS calculated for C31H50N10O8
[MH]  691.3886, found 691.3896.
Enzymatic Characterization—The recombinant WNV protease
(WNV CF40.Gly.NS3pro) was assayed against four hexapeptide sub-
strates corresponding to P6-P1 of known endogenous cleavage sites
NS2A-NS2B (Ac-DPNRKR-pNA), NS2B-NS3 (Ac-LQYTKR-pNA), NS3-
NS4A (Ac-FASGKR-pNA), NS4B-NS5 (Ac-KPGLKR-pNA) with a chro-
mogenic pNA group in the P1 position. Cleavage of the pNA chro-
mophore from the peptide substrates by the WNV protease produced a
detectable color change at 405 nm, allowing protease activity to be
measured. The assay was conducted on a 96-well plate with a final
reaction volume of 200 l containing buffer (plus glycerol and CHAPS
detergent for optimal processing), 0.5 M recombinant protease, and
500 M substrate at 37 °C. After preincubation in separate wells (10
min, 37 °C), catalysis was initiated by mixing substrate with the en-
zyme buffer solution by automatic shaking. The optical density was
measured at 405 nm every 30 s for 10 min in a SpectraMax 250 reader,
and the average change in mOD/min was calculated.
pH dependence was determined over the range 5.5–12.0 using 0.5 M
enzyme, 500 M substrate (Ac-FASGKR-pNA), incubation temperature
37 °C, constant ionic strength (I 5 mM), final volume 200 l, for 50 mM
buffer (MES (pH 5.5–7.0), MOPS (pH 6.5–8.0), Tris (pH 7.5–9.5), CAPS
(pH 10.0–11.0)) containing NaCl, glycerol, CHAPS detergent.
Glycerol dependence was determined by assaying environments of
increasing glycerol content, from 0 to 50% glycerol (5% increments) in
the final volume of 200 l. Glycerol dependence assays contained buffer
with NaCl, glycerol, CHAPS detergent, 0.5 M enzyme, 500 M sub-
strate (Ac-FASGKR-pNA), constant ionic strength (I  5 mM, NaCl), at
37 °C in a final volume 200 l.
Ionic strength dependence was determined for 0–200 mM NaCl in
buffer (with glycerol, CHAPS), 0.5 M enzyme, 500 M substrate (Ac-
FASGKR-pNA), 37 °C in the final volume of 200 l.
Initial reaction velocities were monitored continuously at 405 nm on
a SpectraMax® 250 spectrophotometer, and then interpreted using the
accompanying SoftMax™ Pro software, both from Molecular Devices
Corporation. Subsequent assays for Km determination were performed
under optimal pH, glycerol and ionic strength conditions as determined
by interpretation of the previous pH, glycerol, and ionic strength assays
via SoftMax™ Pro and GraphPad Prism® software.
Optimal assaying conditions, found to be 30% glycerol, pH 9.5, no
added NaCl, were used to determine Km and kcat values measured for
the four pNA-peptide substrates at concentrations ranging from 100 to
3000 M. Results were graphed using GraphPad Prism® version 4.0a
for Macintosh, GraphPad Software, San Diego, CA (www.graphpad.
com), and kinetic parameters calculated from weighted nonlinear re-
gression assuming Michaelis-Menten kinetics (v  Vmax[S]/[S]Km),
kcat values calculated from kcat  Vmax/[E]. Data are reported as the
means of triplicate measurements  S.E.
Homology Modeling—West Nile Virus NS3 protease homology mod-
els were generated using the structures of the Dengue virus NS3
protease without ligand (pdb1BEF), (9) and with Bowman-Birk inhib-
itor (pdb1DF9, subunit B), (9) and hepatitis C virus NS3 protease with
bound cofactor (pdb1A1Q) (8). Models were generated using the Mod-
eler and the Homology module within the InsightII molecular modeling
system (17). All modeling was performed using Silicon Graphics R10000
workstations.
Sequences were aligned using Align 2D, Structure Alignment (Ho-
mology Module, InsightII) and ClustalW alignment (18). Secondary
structure predictions were conducted using web-based PsiPred predic-
tion for each of the three NS3 protease sequences (19). Electrostatic
potential mapping was performed on the WNV NS3 protease model
using the Delphi module in InsightII (20). A four-residue P3-P1 sub-
strate (Thr-Lys-Arg-Gly) was docked into the active site of a homology
model of the WNV NS3 protease using GOLD v2.1 (21). A specified
distance constraint between substrate residue Arg (P1) and WNV pro-
tease Tyr150 (S1), as well as distance and hydrogen bond constraints
between substrate residue Thr (P3) and WNV protease Gly153 (S3) were
used based on our understanding of protease-inhibitor interactions (22,
23).3 The docked structures were ranked for best fitting conformations
using GOLD 2.1 (21).
RESULTS
Design of a Catalytically Active WNV Protease—The single
serine protease within the flaviviral WNV RNA genome pro-
vides an ideal starting point and therapeutic target for re-
search into the design and development of a WNV serine pro-
tease inhibitor. The first step in designing a catalytically active
WNV protease was based on our previous work on the Den-
gue-2 viral protease, for which we identified a minimum se-
quence of 184 residues from the NS3 protease (NS3pro) and 40
residues from the NS2B cofactor (CF40) that are necessary for
catalytic processing of substrates (6, 25). In that work we
created a catalytically active protease construct by fusing CF40
to NS3pro separated by various linkers, the most active con-
struct involving a nonapeptide linker (GGGGSGGGG) as a
replacement for the normal NS2B-NS3A cleavage sequence.
Alignment of the WNV and Dengue virus NS2B-NS3 se-
3 J. D. A. Tyndall, T. Nall, and D. P. Fairlie, submitted for
publication.
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quences (Fig. 2) indicated 53% sequence identity (exact amino
acid match) and 79% sequence similarity (hydrophilicity/pho-
bicity) within the 184 residues of NS3pro. This homology, in-
cluding conserved catalytic residues His51 (H), Asp75 (D), and
Ser135 (S), and oxyanion residue Gly133 (G), gave us confidence
in our alignment. Residue Gly178 in WNV NS3 was not present
in Dengue-2 virus NS3. Alignment of the NS2B cofactor do-
mains displayed 33% sequence identity (exact amino acid
match) and 75% sequence similarity (high and low chemical
similarity). These sequence comparisons suggested that, by
analogy with the Dengure-2 NS2B-NS3 protease, a catalyti-
cally active sequence for WNV NS2B-NS3 protease might sim-
ilarly constitute 40 residues from the NS2B cofactor and 184
residues from NS3, connected via a nonapeptide linker G4SG4
(abbreviated as Gly) in place of the normal NS2B-NS3 cleavage
site sequence. We designated the putative catalytic protease
construct as WNV CF40.Gly.NS3pro. A recombinant construct
was also generated consisting of the 184 residue NS3 protease
domain in the absence of the NS2B cofactor domain to confirm
that activity was dependent on the correct association of the
cofactor, as was previously shown for the Dengue virus equiv-
alent construct (6). We designated this construct WNV NS3pro.
Expression and Purification of WNV NS3pro and WNV
CF40.Gly.NS3pro—The first experimental aim was to express
and purify a recombinant WNV NS3 protease domain and a
catalytically active recombinant WNV protease based on the
recombinant Dengue-2 virus NS3 protease (6). The homologous
WNV recombinant constructs (WNV NS3pro and WNV
CF40.Gly.NS3pro) were produced and cloned into the pQE9
expression vector. The sequence of these constructs and their
insertion into pQE9 was confirmed by automated sequence
analysis.
The pQE9 vector was used because it allowed a high level of
expression, inducible with the addition of IPTG. The addition of
an N-terminal hexahistidine tag enabled ready purification by
Ni2 affinity chromatography. The SDS-PAGE expression pro-
file of pQE9 WNV NS3pro and pQE9 WNV CF40.Gly.NS3pro
are shown in Fig. 3, A and B, respectively and the Ni2 affinity
chromatography of purified WNV CF40.Gly.NS3pro is shown
in Fig. 3C. Fig. 3A shows a major band at 23 kDa, present
only in the bacterial lysates prepared after induction with
IPTG. This band was attributed to recombinant WNV NS3pro
as it is under the control of the T5 promoter and correlates
approximately with the theoretical size of WNV NS3pro pre-
dicted by Vector NTI of 21 kDa. As we had observed previously
with Dengue virus NS3pro (6) following extraction, the major-
ity of the expressed product was found in the insoluble pellet
fraction, with very little present in the soluble fraction. Fig. 3B
shows a major band at 32 kDa, present only in the bacterial
lysates prepared after induction with IPTG. This band was
attributed to recombinant WNV CF40.Gly.NS3pro as it is un-
der the control of the T5 promoter and correlates approxi-
mately with the theoretical size of WNV CF40.Gly.NS3pro
predicted by Vector NTI of 27 kDa. The majority of this ex-
pressed product was present in the soluble fraction, indicating
that the recombinant protein was likely to be folded correctly.
Both recombinants were subsequently purified from the solu-
ble fractions by Ni2 affinity chromatography. Because of the
low level of recombinant WNV NS3pro in the soluble fraction
relatively poor recoveries were obtained. Fig. 3C however
shows that the WNV CF40.Gly.NS3pro recombinant (30 kDa)
was recovered and purified efficiently. The difference in molec-
ular weight estimations between B and C was likely due to the
use of prestained and non-prestained molecular weight mark-
ers, respectively. The two additional bands were attributed to
products of autocatalytic cleavage, since they were not present
in the purification of an inactive recombinant S135A mutant
enzyme (data not shown) consistent with these fragments be-
ing dependent on proteolytic activity. These products were not
expected to have an effect on processing of synthetic peptide
substrates as the rate of autocatalytic cleavage is several or-
ders of magnitude lower than that of peptide substrate cleav-
age and the substrate concentration is far in excess of enzyme
concentration.
Proteolytic Activity—In vivo there are at least seven known
post-translational cleavage sites that are processed by WNV
FIG. 2. Alignment (ClustalW) of recombinant NS3-NS2B protease-cofactor sequences for Dengue (6) and West Nile Virus (18).
Alignment shows catalytic residues Ser135 (S), Asp75 (D), His51 (H) in bold, oxyanion residue Gly 133 (G). 40 residue cofactor domain of NS2B
(underlined) as defined for Dengue type 4 virus (ˆ) (32); exact amino acid match (), high chemical similarity (:), low chemical similarity (.),
insertion/deletions (), and residues (italics) incorporated in construct design. Alignment is numbered from the first residue of the protease
domain.
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protease in the cytoplasm of infected host cells (Fig. 1). Amino
acid residues corresponding to those cleavage sites are dis-
played in Fig. 4. We chose P6-P1 hexapeptides from four of
these sequences to construct putative substrate analogues ter-
minating in a chromophore (para-nitroanilide) at P1. The
putative substrate sequences were Ac-DPNRKR-pNA (NS2A-
2B), Ac-LQYTKR-pNA (NS2B-NS3), Ac-FASGKR-pNA (NS3-
NS4A), and Ac-KPGLKR-pNA (NS4B-NS5). These potential
substrates were to be used to characterize proteolytic activity of
WNV CF40.Gly.NS3pro under a variety of assay conditions,
culminating in an optimum set of conditions that could be used
for more detailed kinetic analysis, and ultimately for inhibitor
screening. A preliminary comparison of these four substrates
suggested that Ac-FASGKR-pNA was processed fastest and
with the highest efficiency (kcat/Km), so that particular sub-
strate was used in the following investigation of factors that
influence substrate processing by the protease. Sufficient pu-
rified WNV NS3pro was obtained to assess its enzymatic prop-
erties against Ac-FASGKR-pNa and was the found not to
cleave the substrate, confirming that the protease is inactive in
the absence of the NS2B cofactor.
Effect of pH on Enzymatic Activity—The WNV NS3 protease
(WNV CF40.Gly.NS3pro) was assayed over a wide pH range
from pH 5.5–11.0, using a variety of buffers suitable for each
pH range: MES (pH 5.5–7.0), MOPS (pH 6.5–8.0), Tris-HCl
(pH 7.5–9.5), CAPS (pH 10.0–11.0). The optimal pH for proteo-
lytic cleavage was determined to be pH 9.5 (Fig. 5A). In the
absence of enzyme, the substrate was resistant to hydrolysis
above the optimal processing pH of 9.5, and was still intact at
pH 12.0. The optimal processing pH of the WNV protease (pH
9.5) is comparable to the optimal processing pH (9.0) that we
found previously for the Dengue-2 virus NS3 protease (6).
Effect of Glycerol on Enzymatic Activity—We had previously
found that glycerol enhances catalytic processing by Dengue
NS3 protease (6), an effect we attributed to minimizing enzyme
aggregation (26). We therefore examined the effect of varying
glycerol concentrations (0–50% v/v) in the final assay volume
on catalytic rate of processing of FASGKR-pNA. There was a
linear concentration dependence on glycerol (Fig. 5B), consist-
ent with increasing glycerol-promoting dissociation of aggre-
gating enzyme molecules and increasing accessibility of the
enzyme active site to substrate. While increasing glycerol con-
tent of the assay environment proved beneficial to processing of
substrates, the increasing viscosity of aqueous glycerol limited
the assay to 30% glycerol in the final assay volume.
Effect of Ionic Strength on Enzymatic Activity—The effect of
increasing ionic strength was tested by adding NaCl (0–200
mM) to the reaction medium. The results (Fig. 5C) clearly show
that increasing ionic strength inhibits the proteolytic process-
ing of the substrate. High NaCl might conceivably be detrimen-
tal by competing with substrate and water molecules for occu-
pancy of the substrate binding active site, thereby inhibiting
substrate processing. Alternatively, NaCl is known to favor
-helicity in peptides, and thus may alter conformational equi-
libria of substrates in solution, rendering them less recogniz-
able to the protease. It has been convincingly demonstrated
elsewhere that all proteases only recognize their substrates
and inhibitor analogues in an extended -strand conformation
(22, 27). Thus, lower proportions of substrates in a -strand
conformation would reduce the catalytic turnover, as observed.
Enzyme Kinetics: Substrates and Inhibitor—The four peptide
substrates, corresponding to the different NS2A-NS2B, NS2B-
NS3, NS3-NS4A, NS4B-NS5 cleavage sites of the WNV RNA
genome, were tested for their capacity to be cleaved by the
WNV protease under the optimal processing conditions out-
lined above (50 mM ethanolamine buffer, pH 9.5; 30% glycerol;
1 mM CHAPS, no added NaCl, 37 °C, final volume 200 l). The
assay was conducted using eight different substrate concentra-
tions ranging from 125 to 3000 M. The results were graphed
according to Michaelis-Menten kinetics v  Vmax[S]/([S]  Km)
FIG. 4. Native WNV polypeptide sequences cleaved by WNV
protease. Eight recognition sequences (P6-P6) and post-translational
cleavage sites (2) known to be processed in host-infected cells by WNV
protease (4, 14, 24). Bold residues indicate P2, P1, and P1residues.
FIG. 3. Expression of the West Nile Virus recombinant proteases. SDS-PAGE expression profiles of WNV NS3pro (A) and WNV
CF40.Gly.NS3pro (B). Lanes show cell lysate before and after the induction of recombinant protein expression with IPTG as well as the
supernatant-containing soluble protein fraction and the pellet fraction containing insoluble protein after centrifugation at 13 krpm for 5 min. The
highlighted bands are only present in samples collected after induction with IPTG and are thus suspected to be the recombinant proteins WNV
NS3pro and WNV CF40.Gly.NS3pro, in A and B, respectively. C, SDS-PAGE purified WNV CF40.Gly.NS3pro. The major species present at
approximately 30 kDa is recombinant protease, bands at 21 and 16 kDa are cleavage fragments.
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(Fig. 5D) in order to calculate the binding affinity constant Km
and the reaction rate kcat ( Vmax/[E]). Kinetic data (Table I)
suggested only small changes in processing rate (kcat) between
the four substrates, with the NS3-NS4A cleavage site being
processed fastest and the NS2B-NS3 cleavage site processed
slowest. The highest affinity substrate (lowest Km) was the
sequence corresponding to the NS3-NS4A cleavage site. The
rank order for highest catalytic efficiency (kcat/Km) of these
pNA substrates was AcFASGKR-pNA (NS3-NS4A)  Ac-
KPGLKR-pNA (NS4B-NS5)  Ac-DPNRKR-pNA (NS2A-
NS2B)  Ac-LQYTKR-pNA (NS2B-NS3). By comparison, cor-
responding processing of Dengue pNA substrates by Dengue-2
CF40.Gly.NS3pro (6) displayed Km and kcat values that were
lower than for the WNV substrates. This suggests greater
catalytic efficiency (kcat/Km) for substrate processing by the
WNV NS3 protease compared with the analogous recombinant
Dengue NS3 protease construct.
Based on this preference for the P6-P1 substrate sequence
corresponding to NS3-NS4A, we also constructed Ac-FAS-
GKR-H with a C-terminal aldehyde and found (Fig. 5E) this to
be a reasonably potent competitive inhibitor (IC50 1 M) of
catalytic processing of Ac-FASGKR-pNA by WNV CF40.
Gly.NS3pro. This potency is despite the fact that the aldehyde
exists in aqueous solution as an equilibrium mixture (Fig. 6)
with a cyclic form, in which the side chain guanidine of Arg has
condensed with aldehyde, and with acetal formed through hy-
dration of the aldehyde. The free aldehyde is likely to be the
active form of this inhibitor (28), but is not present above 5% in
the mixture in aqueous solution, the bulk of the compound
existing in the hydrate form of the aldehyde and in two diaste-
reomeric hemi-aminal cyclic forms (Fig. 6). The modest potency
observed for this inhibitor may be a consequence of the unfa-
vorable position of this equilibrium, with little of the active
form of the inhibitor (free aldehyde) available for interaction
with the active site serine hydroxyl group.
The effect of standard protease inhibitors on processing of
the substrate Ac-FASGKR-pNA by WNV CF40.gly.NS3pro was
also investigated (Fig. 7). Standard serine protease inhibitors
such as benzamidine, FUT-175, PMSF, leupeptin, and TLCK,
failed to show any significant protease inhibition at concentra-
tions of 100 M. Under the same conditions FASGKR-aldehyde
was a significant inhibitor even at a concentration of 10 M
(Fig. 7).
Homology Modeling—In order to provide a structural basis
for further investigations of the WNV protease, for which no
TABLE I
Kinetic parameters for the hydrolysis of synthetic peptide substrates
by WNVCF40.Gly.NS3pro
Hydrolysis was performed at 37 °C, pH 9.5, ethanolamine, 30% glyc-
erol, 1 mM CHAPS.
Substrate (cleavage site) Km kcat kcat/Km
M s1 M1s1
Ac-DPNRKR-pNA (2A-2B) 740  62 1.3  0.04 1756  96
Ac-LQYTKR-pNA (2B-3) 892  95 1.1  0.05 1233  86
Ac-FASGKR-pNA (3–4A) 450  45 1.9  0.06 4222  313
Ac-KPGLKR-pNA (4B-5) 821  85 1.5  0.06 1827  124
FIG. 6. Chemical form of aldehyde inhibitor in water.
FIG. 5. Enzymatic characterization
of WNV CF40.Gly.NS3pro. Effects of
pH, buffer, glycerol content, ionic
strength, and a substrate-derived inhibi-
tor on proteolytic processing by
WNV.CF40Gly.NS3pro construct. A, ef-
fect of pH. Substrate analogue Ac-FAS-
GKR-pNA (NS3-NS4A cleavage site),
ionic strength (NaCl 10 mM), glycerol con-
tent (30% of final volume) over a range of
pH buffers (50 mM): MES (pH 5.5–7.0),
MOPS (pH 6.5–8.0), Tris-HCl (pH 7.5–
9.5), CAPS (pH 10.0–12.0) (f); and in ab-
sence of enzyme (Œ). B, effect of glycerol.
Same conditions as A except [glycerol] 
0–50% (f), and pH 9.0 (Tris buffer). C,
effect of ionic strength. Same conditions
as B except [glycerol]  20% of final vol-
ume and varying ionic strength (NaCl: 0
mM, 10 mM, 25 mM, 50 mM, 75 mM, 100
mM, 125 mM, 150 mM, 200 mM) (f). D,
effect of substrate on protease processing.
Para-nitroanilide substrates correspond-
ing to cleavage sites NS2A-2B (Ac-DPN-
RKR-pNA; f, NS2B-NS3 (Ac-LQYTKR-
pNA; Œ), NS3-NS4A (Ac-FASGKR-pNA;
), NS4B-NS5 (Ac-KPGLKR-pNA;) un-
der optimal assay conditions (50 mM eth-
anolamine buffer, pH 9.5, 30% glycerol, 1
mM CHAPS, 37 °C, final volume of 200
l). E, effect of inhibitor. Processing of
Ac-FASGKR-pNA under same conditions
as in D but with varying concentrations
(only 1–10 M [I] shown) of aldehyde in-
hibitor Ac-FASGKR-H. IC50 1 M. In all
cases, bars indicate S.D. from the mean
resulting from the average of three
replicates.
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current crystal structure exists, a homology structural model
was generated based on the crystal structures of two flavivirus
proteases, the Dengue virus NS3 protease (pdb1BEF and
pdb1DF9) (9), and the hepatitis C virus NS3 protease
(pdb1A1Q) (8). The Dengue virus NS3 and hepatitis C virus
proteases were selected as a basis for the WNV protease model
for their sequence homology (with Dengue NS3pro, Fig. 2) and
structural homology (HCV, with lower sequence homology),
providing a suitable reference for generating a WNV NS3 pro-
tease homology model. As the flaviviral NS3 proteases require
a cofactor for activity, the HCV protease structure (pdb1A1Q)
(8) containing the HCV NS4A cofactor was used for the WNV
protease homology model, thus taking into account the role of
the WNV NS2B cofactor in the activation of the WNV NS3
protease.
Whereas sequence identity between the HCV protease and
WNV protease or HCV protease and Dengue viral protease was
much less (14.5% and 15.5% respectively), the knowledge of
high structural homology based on a previous study of HCV
and Dengue virus proteases allowed additional structural ref-
erence for the generation of the model. Studies by Brinkworth
et al. (25) elucidated a model of Dengue virus NS3 protease
based on the HCV NS3 protease crystal structure, despite low
sequence identity. This has since been confirmed by a crystal
structure for Dengue virus NS3 protease (pdb1DF9), used in
the current WNV homology model construction. Sequence
alignment of the HCV protease and WNV protease or HCV
protease and Dengue virus protease yielded 50 and 59% simi-
larity respectively, giving insight into the structural similarity
between the three proteases.
The HCV model with NS4A cofactor allowed the generation
of a WNV protease and potential cofactor model not seen in the
Dengue virus crystal structure. The Dengue NS3 crystal struc-
ture in complex with mung bean Bowman-Birk inhibitor
(pdb1DF9) illustrated the key interactions in the active site of
the Dengue NS3 protease. The Dengue NS3 structure provided
a useful reference for the development of WNV protease-sub-
strate interaction studies. Knowledge of endogenous cleavage
sites was later used in substrate docking and active site stud-
ies, with a view to designing an early substrate-based inhibitor
of the West Nile Virus protease.
Numerous models were generated, based on comparisons
between the different structures and using different sequence
alignment techniques, in order to examine different possibili-
ties for the WNV protease structure. The final model used for
analysis of putative substrate interactions in the active site
was based on the Dengue NS3 protease complexed with the
Bowman-Birk inhibitor (pdb1DF9, subunit B). The -carbon
traces of the WNV model and the Dengue-2 viral protease
crystal structure were very similar.
Based on the endogenous cleavage sites of the WNV NS3
protease, and their P1, P2 dibasic specificity, a four residue
P3-P1 substrate (Thr-Lys-Arg-Gly) was docked into the active
site of the WNV protease model in order to analyze the proba-
ble binding interactions between the substrate and WNV pro-
tease (Fig. 8). When the Arg at P1 is docked into the protease
S1 subsite, residues Tyr150, Asp129, Ser163, Val115, and Ile165
are in close proximity (Fig. 8). It seems likely that Arg makes
an important pi-cation interaction with Tyr150 in the deep S1
pocket. The P2 substrate residue Lys can interact with prote-
ase S2 subsite residues Asn152, Asp75, Gly151, and His51 (Fig.
8). The S2 subsite is fairly exposed, but a hydrogen bond may
be formed between Lys at P2 and Asn152 at S2. The catalytic
triad is also exposed and lies adjacent to the P2 pocket. The P3
Thr residue exhibited a potential interaction with protease
subsite S3 residues Gly153 and Ile155 (Fig. 8). The P1 Gly
residue may interact with protease subsite S1 by hydrogen
bonding to Thr132 and is in close proximity to Ala36 (Fig. 8).
Analysis of these interactions and their relative importance
suggested possible mutagenesis of the active site residues
Ser163, Tyr150, Asp129, and Asn152.4
DISCUSSION
West Nile Virus infections have increased dramatically over
the past decade and the associated morbidity and mortality
have increased the urgency for antiviral therapies (29). Ratio-
nally devised treatments for WNV infections might also become
prototypes for developing antiviral therapies for other flavivi-
rus infections. A single protease enzyme within the WNV ge-
nome is known to be responsible for critical virus-mediated
post-translational cleavages of the polypeptide encoding all the
structural and functional viral proteins that ultimately provide
the replicative machinery for virus amplification and assembly
4 K. J. Chappell, T. A. Nall, M. J. Stoermer, N.-X. Fang, J. D. A.
Tyndall, D. P. Fairlie, and P. R. Young, manuscript in preparation.
FIG. 7. Inhibitor profile of WNV CF40.Gly.NS3pro. A range of
inhibitors were tested for their activity (S.E.) against WNV
CF40.Gly.NS3pro. Test compounds were preincubated with 0.5 M
WNV CF40.Gly.NS3pro for 10 min at 37 °C followed by addition of the
substrate Ac-FASGKR-pNA substrate (500 M) in 50 mM glycine-NaOH
buffer, pH 9.0, 30% glycerol and 1 mM CHAPS. Inhibitors tested were:
1, no inhibitor control; 2, benzamidine (100 M); 3, FUT-175 (100 M);
4, PMSF (100 M); 5, FASGKR-aldehyde inhibitor (10 M); 6, leupeptin
(100 M); 7, TLCK (100 M).
FIG. 8. Homology-modeled structure of West Nile Virus NS3
protease showing putative interactions between WNV-NS3 pro-
tease active site residues (S3, S2, S1, S1) and substrate.
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into new virus particles. Inhibition of that protease has the
capacity therefore to prevent viral replication. The present
study was aimed at producing and characterizing the first
catalytically active recombinant WNV protease.
To construct a recombinant West Nile Virus protease, we
took advantage of the sequence homology between WNV and
Dengue-2 virus NS2B-NS3 proteins (Fig. 2) and our previous
work that successfully led to a recombinant Dengue virus pro-
tease (6). In summary, we adapted the corresponding WNV
sequences of the putative minimum NS2B cofactor domain and
of the minimum NS3 protease domain and linked them to-
gether with a nonapeptide (G4SG4) replacement for the NS2B-
NS3A native cleavage site. The result was a catalytically active
recombinant WNV protease, designated WNV CF40.Gly.-
NS3pro, which is active only with the appended cofactor
domain.
We characterized the enzyme processing properties of the
recombinant WNV protease, identifying optimal buffers, pH,
and diluents to maximize proteolytic activity. The assay, in-
volving the use of hexapeptide substrates corresponding to
P6-P1 segments of cleavage sites within the WNV genome
fused to a chromogenic moiety (para-nitroanilide) at P1, has
the potential for rapidly screening prospective inhibitors of the
enzyme. Indeed, based on one of the substrates examined, we
also generated the first small molecule inhibitor (IC50 1 M) of
the WNV protease.
A striking feature of the enzymatic activity was the similar-
ity between catalytic properties of the recombinant proteases of
Dengue virus and West Nile Virus. The high pH (8–10) re-
quired for processing is unusual and cannot yet be satisfacto-
rily explained, but may indicate a level of virus-mediated con-
trol over replication, since processing at physiological pH would
be 1% of the measured rates at pH 9.0.
The native cleavage sites that are processed by WNV prote-
ase in vivo (Fig. 1) feature two conserved basic residues at
positions P1 and P2 (Arg, Lys, respectively, Fig. 4) and a small
residue at P1 (Gly, Ser), indicating a signal sequence for the
cleavage of the WNV genome by its NS2B-NS3 protease. This
dibasic recognition sequence is almost completely conserved
throughout the flaviviral proteases and is unusual in compar-
ison with host cellular enzymes. Indeed we have now shown for
both the Dengue-2 (6) and WNV virus proteases (Fig. 7) that a
panel of conventional serine protease inhibitors was inactive
against that protease. This feature promises novelty for the
design of potent inhibitors that may be selective for flavivirus
proteases over host cellular proteases. Realization of a potent
and selective inhibitor of WNV protease may result in an at-
tractive lead for development of an antiviral treatment for
WNV, and perhaps with potential for broad spectrum inhibi-
tion of flaviviruses in general.
Toward further studies, aimed at developing even more po-
tent and selective inhibitors of WNV protease as candidate
antiviral drugs, we also created a three-dimensional structural
model of the protease. That model suggests binding sites in the
protease for both the NS2B cofactor and small molecule sub-
strates/inhibitors that can occupy the active site, and reveals
putative enzyme-ligand interactions that should provide valu-
able insights for inhibitor development. This information could
conceivably be combined with the known requirement in pro-
tease active sites of the extended -strand ligand conformation
(22, 27),3 and the growing number of -strand mimetics (30, 31)
becoming available as templates for design of substrate-based
inhibitors of proteases.
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